A study to evaluate the safety and tolerability of AZD7442 in Healthy Chinese Adults

Study identifier:D8850C00007

ClinicalTrials.gov identifier:NCT05437289

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

A Phase I Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD7442 in Healthy Chinese Adults

Medical condition

Coronavirus disease 2019 (COVID-19), Healthy Volunteer

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD7442 IM, Placebo IM, AZD7442 IM, Placebo IM, AZD7442 IV, Placebo IV, AZD7442 IV, Placebo IV

Sex

All

Actual enrollment

61

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 09 Oct 2021
Primary Completion Date: 27 Nov 2021
Estimated Study Completion Date: 10 Feb 2023

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Other

Verification:

Verified 01 Nov 2022 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria